Christos Damaskos, Nikolaos Garmpis, Dimitrios Dimitroulis, Georgios Kyriakos, Evangelos Diamantis
Journal: Acta medica (Hradec Kralove) 2022;64(4):200-203
PMID: 35285441
PURPOSE
Our aim is to clarify if there is an association between the TSI levels and the development of thyroid carcinoma in patients with Grave's disease.
METHODS
A systematic search concerning original studies from 2010 to 2020 was carried out through the databases PubMed, EMBASE and Cochrane, according to the PRISMA (Preferred Reporting Items for Systematic reviews and Meta-Analyses) guidelines. The terms used are 'Graves' disease' and /or 'Incidental Papillary thyroid cancer' and 'TSI' levels. Retrospective studies upon the subject were concluded in the analysis.
RESULTS
Only three retrospective studies were found involving 916 patients with Graves' disease and Euthyroid goiter. No significant correlation has been found between TSI and the occurrence of thyroid carcinoma in patients with Graves' disease.
CONCLUSION
Very little research has been conducted upon the subject. More assays are required in order to identify a possible prognostic role of TSI levels in Papillary thyroid carcinoma in patients with Graves disease.
Full Text Sources:
Medical:
© Copyright 2026, Nutrition Evidence
We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.